As of June 30, 2018, BioSpecifics has received over $146.2 million from partnerships under the XIAFLEX franchise.

BioSpecifics is partnered with Endo for CCH (marketed in the U.S. under the trade name XIAFLEX) and Endo continues to manage the research and development of XIAFLEX and CCH for their licensed indications.

Under the terms of the partnership agreement, BioSpecifics is eligible for future low double-digit royalties as a percentage of worldwide net sales (independent of clinical indication, territory and sales volume), additional mark-up on cost of goods sold (COGS) in U.S. and sales made in any other country where Endo sells the product directly or through affiliate sublicensees and modest milestones for additional indications and regulatory submissions worldwide. Currently licensed rights cover the indications of Dupuytren's contracture, Peyronie's disease, frozen shoulder, cellulite, lateral hip fat, plantar fibromatosis and human and canine lipomas.